Reduced PHLPP Expression Leads to EGFR-TKI Resistance in Lung Cancer by Activating PI3K-AKT and MAPK-ERK Dual Signaling

Abstract excerpt

Background Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are effective in advanced EGFR-mutation non-small cell lung cancer (NSCLC) but the magnitude of tumor regression varies, and drug resistance is unavoidable. The pleckstrin homology domain leucine-rich repeat protein phosphatase (PHLPP) levels are reduced or lost and acts as a tumor suppressor in many cancers. Here, we hypothesized...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Lung Cancer Treatments and Mutations
• Share to PI3K/AKT/mTOR signaling in cancer
• Share to Protein Tyrosine Phosphatases